Thrombocytosis induced by nadroparin calcium
10.3760/cma.j.cn114015-20200708-00753
- VernacularTitle:那屈肝素钙致血小板增多症
- Author:
Piaopiao ZHAO
1
;
Xin WANG
1
;
Feimei FANG
1
Author Information
1. 浙江省东阳市人民医院呼吸内科，东阳 322100
- Publication Type:Journal Article
- Keywords:
Nadroparin;
Thrombocytosis
- From:
Adverse Drug Reactions Journal
2021;23(3):150-151
- CountryChina
- Language:Chinese
-
Abstract:
A 64-year-old male patient with comminuted intertrochanteric fracture of right femur received subcutaneous injection of 4 100 U nadroparin calcium once daily for anticoagulant treatment due to pulmonary embolism and thrombosis of both lower limbs before operation. His platelet count (PLT) was 166×10 9/L before the treatment. After 5 days of treatment, the dose of nadroparin calcium was increased to 4 100 U once per 12 h. On the 8th day after the dose increase, the patient′s PLT increased to 800×10 9/L. Thrombocytosis was diagnosed, which was considered to be related to nadroparin calcium. The drug was stopped and replaced by rivaroxaban 20 mg once daily orally. Five days later, the patient′s PLT decreased to 590×10 9/L; 34 days later, PLT was 297×10 9/L.
